original articlesbreast tumorsTrastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†
breast tumors
Under a Creative Commons license
open access
ado-trastuzumab emtansine
T-DM1
metastatic breast cancer
central nervous system metastasis
Cited by (0)
- †
These data were presented in part at: The 36th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; 10–14 December 2013. I. Krop, N. Lin, K. Blackwell et al. Efficacy and safety of trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer and central nervous system metastases: results from a retrospective exploratory analysis of EMILIA.
- ‡
Present Address: Department of Gynecology, University of Ulm, Ulm, Germany.
Copyright © 2015 THE AUTHORS. Published by Elsevier Ltd.